Preprint at (2016)
Jena, MD PhD Department of Health Care Policy, Harvard Medical School , Boston, MA Department of Medicine, Massachusetts General Hospital , Boston, MA National Bureau of Economic Research , Cambridge, MA, Nicholas Stucky, MD PhD Truveta, Inc , Bellevue, WA With the growing popularity of GLP-1 RAs, concerns have been raised that the expanded use may occur amongst patients with less clinical need
Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history
Eubig PA, Aguiar A, Schantz SL
Most patients notice changes within 2-3 months of starting treatment, often coinciding with the first 5-10% weight loss
Were here to break down what this trend means and how our specialized program, featuring prescription Wegovy and Zepbound, is designed to meet this exact demand-100% virtually